Danone has announced a targeted recall of a limited number of infant formula batches produced in Ireland, following updated guidance from local food safety authorities. The recall affects fewer than 0.5% of total European Specialized Nutrition production and covers products distributed in five markets across Europe and Asia. Danone’s routine quality controls and additional targeted analyses confirmed that the recalled batches met all internal safety and regulatory standards, but the company elected to withdraw them to comply with evolving official recommendations and to uphold consumer trust in its infant nutrition portfolio.

In response to the sector-wide toxin contamination concerns that began with other industry players, Danone has intensified its surveillance procedures, introducing an extra layer of microbial and chemical testing for all infant formula lines. The company now conducts over 1,200 safety tests per week in its Irish manufacturing facility, doubling the frequency of pre-release assays compared with 2024. Danone emphasizes that no safety breaches were detected in non-recalled batches and that the recall is a precautionary measure aligned with guidance from the European Food Safety Authority and national agencies.

Specialized Nutrition accounts for approximately 15% of Danone’s €27.4 billion in 2024 sales. Although the recall is limited in scope, Danone anticipates a short-term sales disruption of around €20 million in the first quarter of 2026 within the affected markets. To mitigate potential brand erosion, the company has deployed an enhanced consumer outreach program, including a dedicated careline supporting over 30,000 parent inquiries to date, and a digital campaign reinforcing Danone’s long-standing food-safety commitments. External brand-tracking data indicate that overall consumer confidence in Danone’s infant formula remains above 90%.

Danone is leveraging its Renew strategy to restore growth and competitiveness in Specialized Nutrition, targeting mid-single-digit organic revenue growth by 2028. The company has accelerated investments in its Irish infant formula facility, allocating €50 million this year to expand capacity and implement next-generation contamination-control systems. Concurrently, Danone is pursuing B Corp certification improvements in its nutrition arm, following its global B Corp achievement in 2025, and is exploring strategic partnerships to introduce novel, clean-label ingredients aimed at further strengthening its nutritional leadership.